Dr. Taub quoted in Dermatology Times

August 5, 2016
SHARE THIS ARTICLE

Dermatology Times
August 5, 2016
By Lisette Hilton

"“Amy Forman Taub, M.D., medical director, founder of Advanced Dermatology/skinfo.com, in Lincolnshire, Ill., and assistant clinical professor of dermatology at Northwestern University Medical School, Chicago, is among the researchers for DefenAGE. She says that to understand the basic cosmeceutical application of stem cells and how they regulate biological activity within the skin, dermatologists must first understand that there is no such thing as “generic” stem cell batch.

“Similar to people discussing curing cancer, as if it were all one illness, there are a myriad of different stem cell types,” Dr. Taub says. “Scientists from various groups have identified at least 10 stem cell types that reside within the hair follicle, although not all of them stimulate hair growth. Specifically one, the LGR6+ stem cell, is targeted by Defenage, the new skincare product. Subsequent to application of this topical product on the skin, this LGR6+ stem cell is stimulated to increase production of new keratinocytes.

LGR6+ usually springs into action after we have experienced a cut or scrape, a reparative mechanism.”

This is a paradigm shift away from the application of a “soup” of multiple different growth factors to the targeting of one or multiple specific pathways of growth within the body.

“This change in thought reminds me of the shift from generalized reduction of the immune system with methotrexate or cyclosporine for psoriasis and toward specific receptor blockage in the aberrant biochemical pathway,” Dr. Taub says. “Hair growth is a very complex biological process in which there are probably four to 10 factors that play a role at any given time. If we could target the specific molecules responsible for the pathways leading to the signal to hair follicles to change from a telogen hair to an anagen hair, then we would be closer to growing hair. PRP has been very popular but does depend on the older paradigm of flooding the tissue with intact growth factors (e.g., those in the serum) and hoping these native proteins or peptides will trigger growth. Newer technology will use biomimetic or manufactured peptides that are specific for multiple pathways and will be used simultaneously to turn on growth.” Read Full Article.